Stock Performance and Market Context
On 03 Jul 2026, Parmax Pharma Ltd opened and traded at Rs.82.88, marking its highest-ever price level. The stock outperformed its sector by 0.7% on the day, registering a daily gain of 1.99% compared to the Sensex’s 0.68% rise. This price surge is part of a broader upward trend, with the stock exhibiting a consecutive gain streak spanning 19 trading days. Over this period, Parmax Pharma has delivered an impressive 81.24% return, signalling robust investor confidence and momentum.
When viewed against broader market benchmarks, the stock’s performance stands out distinctly. Over the past one year, Parmax Pharma has appreciated by 107.20%, while the Sensex declined by 6.26%. Year-to-date, the stock has surged 144.99%, contrasting with the Sensex’s fall of 8.44%. Even over a three-year horizon, Parmax Pharma’s 180.95% gain far exceeds the Sensex’s 19.67% rise, highlighting the company’s exceptional relative strength in the market.
Technical Indicators and Trend Analysis
The technical outlook for Parmax Pharma remains bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the current uptrend. The overall technical trend shifted to bullish on 08 Jun 2026 at a price of Rs.48.81, marking a clear inflection point in momentum.
Key technical indicators support this positive stance. Weekly and monthly MACD readings are bullish, as are Bollinger Bands and the KST indicator. The Dow Theory assessment is mildly bullish, while the RSI shows a bearish signal, suggesting some caution in momentum strength. Immediate support is established at the 52-week low of Rs.22.60, with major resistance levels previously noted at Rs.65.27 (20 DMA), Rs.38.62 (100 DMA), and Rs.35.93 (200 DMA) now decisively surpassed. The current 52-week high of Rs.82.88 represents a far resistance level that the stock has successfully breached.
Volume and Delivery Trends
Delivery volumes have shown a significant increase, with a 1-month delivery change of 278.41% and a 1-day delivery change of 22.26% compared to the 5-day average. On 02 Jul 2026, the volume stood at 3.62 thousand shares, slightly above the 5-day average of 2.96 thousand. This elevated delivery volume indicates strong participation in the stock’s recent rally, supporting the price appreciation.
Valuation Metrics and Financial Overview
Despite the stock’s strong price performance, Parmax Pharma remains a loss-making entity on a trailing twelve-month basis, with no reported price-to-earnings ratio due to negative earnings. The price-to-book value stands at -4.94x, and EV/EBITDA and EV/EBIT ratios are negative at -11.53x and -8.97x respectively, reflecting the company’s current financial structure. The EV/Sales ratio is 3.41x, while EV/Capital Employed is 8.74x. Dividend metrics are not applicable as the company has not declared dividends.
The 52-week price range highlights the stock’s substantial appreciation, with the current price at Rs.82.88 representing a 266.73% increase from the 52-week low of Rs.22.60. This wide range underscores the stock’s volatility and the scale of its recent gains.
Quality and Financial Trends
Parmax Pharma’s overall quality grade is assessed as below average, reflecting challenges in long-term financial performance. Management risk, growth, and capital structure are all rated below average. The company has experienced a 5-year sales decline of 14.30% and a significant 5-year EBIT contraction of 225.63%. Average EBIT to interest coverage is weak at 0.66x, though the company benefits from negative net debt, indicating a net cash position with an average net debt to equity ratio of -1.77.
Other quality indicators include a tax ratio of 100%, zero dividend payout, no promoter share pledging, and low institutional holdings. Average return on capital employed (ROCE) is negative at -28.89%, while average return on equity (ROE) is modest at 5.12%. The company’s sales to capital employed ratio stands at 2.44x.
Short-term financial trends remain negative as of March 2026, with net sales over the latest six months declining by 31.23% to Rs.7.64 crores and profit after tax for nine months shrinking by 50.12% to a loss of Rs.3.39 crores. Quarterly profit before tax excluding other income also remains negative at Rs.-2.30 crores. However, the quarterly earnings per share (EPS) reached its highest level at Rs.-1.55, indicating some improvement in earnings performance.
Market Sentiment and Rating Update
MarketsMOJO currently assigns Parmax Pharma a Mojo Score of 31.0 with a Sell grade, upgraded from a previous Strong Sell rating on 08 Jun 2026. The company is classified as a micro-cap within the Pharmaceuticals & Biotechnology sector. This rating reflects the balance between the stock’s strong price momentum and underlying financial and quality challenges.
Summary
Parmax Pharma Ltd’s attainment of an all-time high price of Rs.82.88 on 03 Jul 2026 marks a significant milestone in its market trajectory. The stock’s sustained rally over 19 consecutive days and substantial outperformance relative to the Sensex and sector benchmarks highlight a period of exceptional market performance. While the company’s financial fundamentals and quality metrics present areas of concern, the technical indicators and volume trends confirm a robust bullish trend. This achievement underscores the dynamic nature of Parmax Pharma’s stock movement within the Pharmaceuticals & Biotechnology sector.
